Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection

Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection REVIEW URRENT Monoclonal antibodies to host cellular receptors PINION for the treatment and prevention of HIV-1 infection a,b b Craig Pace and Martin Markowitz Purpose of review Clinically relevant monoclonal antibodies (mAb) to host cellular receptors have been generated to both the CD4 receptor and the CCR5 coreceptor, cell surface proteins critical for HIV-1 entry. Ibalizumab is a novel humanized mAb that binds to a conformational epitope on CD4 and blocks entry of HIV-1. It has broad and potent antiviral activity in vitro and in vivo. PRO 140 is a humanized mAb that binds to the CCR5 coreceptor and inhibits CCR5-tropic HIV-1 by interfering with viral entry. Antiviral activity has been demonstrated both in vitro against R5 viruses and in vivo in HIV-1-infected individuals harboring CCR5- tropic virus. Recent findings Both antibodies have been administered intravenously in early-phase clinical trials, and current emphasis is on the development of formulations that can be administered subcutaneously. Most recently, bispecific antibodies combining either ibalizumab or PRO 140 with anti-Env broadly neutralizing antibodies have been constructed with vastly improved in-vitro neutralizing profiles, and may offer substantial advantages in the clinic. Summary mAb to host cellular receptors particularly when combined with broadly neutralizing antibodies http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection

Current Opinion in HIV and Aids , Volume 10 (3) – May 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/monoclonal-antibodies-to-host-cellular-receptors-for-the-treatment-and-glvYOBNh35

References (37)

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000146
pmid
25700204
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT Monoclonal antibodies to host cellular receptors PINION for the treatment and prevention of HIV-1 infection a,b b Craig Pace and Martin Markowitz Purpose of review Clinically relevant monoclonal antibodies (mAb) to host cellular receptors have been generated to both the CD4 receptor and the CCR5 coreceptor, cell surface proteins critical for HIV-1 entry. Ibalizumab is a novel humanized mAb that binds to a conformational epitope on CD4 and blocks entry of HIV-1. It has broad and potent antiviral activity in vitro and in vivo. PRO 140 is a humanized mAb that binds to the CCR5 coreceptor and inhibits CCR5-tropic HIV-1 by interfering with viral entry. Antiviral activity has been demonstrated both in vitro against R5 viruses and in vivo in HIV-1-infected individuals harboring CCR5- tropic virus. Recent findings Both antibodies have been administered intravenously in early-phase clinical trials, and current emphasis is on the development of formulations that can be administered subcutaneously. Most recently, bispecific antibodies combining either ibalizumab or PRO 140 with anti-Env broadly neutralizing antibodies have been constructed with vastly improved in-vitro neutralizing profiles, and may offer substantial advantages in the clinic. Summary mAb to host cellular receptors particularly when combined with broadly neutralizing antibodies

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: May 1, 2015

There are no references for this article.